The estimated Net Worth of Chaitan Phd Khosla is at least $112 mil dollars as of 11 August 2020. Chaitan Khosla owns over 2,499 units of Protagonist Therapeutics Inc stock worth over $111,930 and over the last 8 years Chaitan sold PTGX stock worth over $0.
Chaitan has made over 1 trades of the Protagonist Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Chaitan exercised 2,499 units of PTGX stock worth $4,723 on 11 August 2020.
The largest trade Chaitan's ever made was exercising 2,499 units of Protagonist Therapeutics Inc stock on 11 August 2020 worth over $4,723. On average, Chaitan trades about 312 units every 0 days since 2016. As of 11 August 2020 Chaitan still owns at least 2,499 units of Protagonist Therapeutics Inc stock.
You can see the complete history of Chaitan Khosla stock trades at the bottom of the page.
Chaitan's mailing address filed with the SEC is C/O PROTAGONIST THERAPEUTICS, INC., 7707 GATEWAY BLVD., SUITE 140, NEWARK, CA, 94560.
Over the last 8 years, insiders at Protagonist Therapeutics Inc have traded over $11,629,969 worth of Protagonist Therapeutics Inc stock and bought 3,007,840 units worth $35,519,073 . The most active insiders traders include Capital Partners Gp, L.L.C...., & Johnson Johnson & Johnson... y X L.P.Canaan Partners X Llc.... On average, Protagonist Therapeutics Inc executives and independent directors trade stock every 37 days with the average trade being worth of $2,387,307. The most recent stock trade was executed by William D. Waddill on 24 July 2024, trading 8,000 units of PTGX stock currently worth $103,040.
protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist
Protagonist Therapeutics Inc executives and other stock owners filed with the SEC include: